FDA-approved monoclonal antibodies such as rituximab (anti-CD20) and trastuzumab (anti-CD19) are aimed at bringing NK cells within proximity of tumor cells and activating ADCC function to kill the tumor (102). The gene discussed is CD19; the disease is neoplasm.